Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report)'s share price dropped 3.2% during mid-day trading on Wednesday . The company traded as low as $10.77 and last traded at $10.78. Approximately 1,158 shares were traded during trading, a decline of 81% from the average daily volume of 6,180 shares. The stock had previously closed at $11.14.
Wall Street Analysts Forecast Growth
PHAR has been the subject of a number of research reports. Oppenheimer increased their price objective on Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a report on Friday, March 14th. HC Wainwright reissued a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a report on Thursday, March 20th.
Check Out Our Latest Analysis on PHAR
Pharming Group Stock Up 0.4%
The firm has a market capitalization of $761.26 million, a PE ratio of -55.95 and a beta of 0.02. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.76 and a quick ratio of 2.00. The company has a 50-day moving average price of $9.76 and a 200 day moving average price of $9.21.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.03. The firm had revenue of $79.09 million for the quarter, compared to analysts' expectations of $67.74 million. Pharming Group had a negative return on equity of 6.01% and a negative net margin of 4.14%. Analysts forecast that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current year.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
